The $700M upfront transforms Nurix's balance sheet and funds substantial clinical development without dilution. Traders should watch for upcoming clinical data readouts in CLL, MS, and CSU which will drive the near-term binary outcomes. The deal significantly reduces risk given Roche's global infrastructure and credibility.
Price Chart
Executive Summary
Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, an oral BTK degrader, across oncology, immunology, and neurology. Nurix receives $700M upfront and is eligible for up to $2.3B in milestones, with 50/50 U.S. profit sharing and tiered royalties on ex-U.S. sales. This deal provides significant non-dilutive capital, validates Nurix's platform, and de-risks expansion into large indications like multiple sclerosis and chronic spontaneous urticaria, making it a transformative event for the company.
Key Financial Metrics
Key Facts
- Nurix receives $700 million upfront cash payment from Roche.
- Total potential milestone payments up to $2.3 billion.
- Development costs shared 40% Nurix / 60% Roche.
- U.S. profits and losses split equally; Nurix receives royalties (low- to high-teens) on ex-U.S. sales.
- Development plan includes pivotal CLL trials and Phase 2 trials in multiple sclerosis and chronic spontaneous urticaria.
- Bexobrutideg is a brain-penetrant oral BTK degrader with potential advantages over BTK inhibitors.
- Goldman Sachs acted as exclusive financial advisor to Nurix.
Financial Impact
$700M upfront cash payment; up to $2.3B total milestones; 50/50 U.S. profit share; tiered ex-U.S. royalties in low- to high-teens
Risk Factors
- Clinical trial execution and regulatory approval risks across multiple indications
- Shared development costs (40% Nurix) may strain resources if timelines extend
- Potential for HSR antitrust review delays or conditions
- Competitive landscape from existing BTK inhibitors and emerging degraders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307775 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 29d ago | Insider Cluster | $25.32 $25.10 | ▼ −0.87% | ▲ +0.28% | $22.99 (−9.20%) |
Aug 5, 2026 8w ago | Insider Cluster | $25.22 $27.19 | ▲ +7.81% | ▲ +6.60% | $22.99 (−8.84%) |
Aug 5, 2026 8w ago | Insider Cluster | $25.12 $26.63 | ▲ +6.01% | ▲ +5.66% | $22.99 (−8.48%) |
Aug 5, 2026 8w ago | Insider Cluster | $25.12 $26.63 | ▲ +6.01% | ▲ +5.66% | $22.99 (−8.48%) |
Aug 3, 2026 8w ago | Insider Cluster | $24.69 $25.96 | ▲ +5.14% | ▲ +5.24% | $22.99 (−6.89%) |
Jul 30, 2026 9w ago | Insider Cluster | $23.21 $25.53 | ▲ +10.00% | ▲ +6.48% | $22.99 (−0.95%) |
Jul 9, 2026 12w ago | Press Release | $23.06 $23.07 | ▲ +0.04% | ▲ +0.60% | $22.99 (−0.30%) |
Jul 2, 2026 13w ago | Insider Cluster | $23.97 $24.69 | ▲ +3.00% | ▲ +2.07% | $22.99 (−4.09%) |
Jun 11, 2026 16w ago | Institutional Cluster | $16.98 $17.12 | ▲ +0.82% | ▲ +0.39% | $22.99 (+35.39%) |
Jun 8, 2026 16w ago | 8-K | $15.64 $17.04 | ▲ +8.95% | ▲ +6.84% | $22.99 (+46.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access